The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment

January 2006
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p4
Academic Journal
This article reports on a study conducted to examine the efficacy of adefovir dipivoxil in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. 120 patients with HBeAg-negative chronic hepatitis B and compensated liver disease, who had received treatment with adefovir dipivoxil during the previous 48 weeks as part of a randomized placebo-controlled trial were studied. At the end of the second 48 weeks, the decreased levels were maintained in the adefovir group, but not in the placebo group, in which reversion to near-baseline values occurred within 4 to 8 weeks of switching to placebo.


Related Articles

  • Long-term lamivudine benefits children with hepatitis B.  // Nursing Standard;2/13/2008, Vol. 22 Issue 23, p15 

    The article reports on the result of the study concerning the utilization of lamivudine in the treatment of children suffering from chronic hepatitis B. It was conducted through a randomized trial study which was participated by 151 children and were administered with lamivudine and placebo for...

  • Comparison of Two Recombinant Hepatitis B Vaccines. Nejad, Hasan Nikui; Ghorbani, Gholamali; Razaghi, Reza; Akbari, Hossain // Hepatitis Monthly;Summer2009, Vol. 9 Issue 3, p201 

    Background and Aims: Hepatitis B virus (HBV) infection is an important public health problem. Hepatitis B vaccine induces protective response in the majority of vaccinated persons. In our country, we do not have any evaluation for the efficacy of each type of vaccines used in adult and our...

  • HEPATITIS B AND RENAL TRANSPLANTATION: DANGLING THE SWORD OF DAMOCLES? Ryan, Michael J.; Johnson, David A.; Cattau Jr., Edward L. // American Journal of Gastroenterology;Dec1992, Vol. 87 Issue 12, p1882 

    Comments on a study on the increased risk of fatal liver disease in renal transplant patients who are hepatitis B antigen and/or hepatitis B virus DNA positive by Fairley C. R. et al, published in a 1991 issue of "Transplantation." Abstract of the study; Key findings; Criticisms.

  • HEPATITIS B. Kassianos, George // Pulse;12/10/2005, Vol. 65 Issue 48, p43 

    The article presents the author's view on Hepatitis B. George Kassianos shares his insights gained from working as a general practitioner. He informed that tattoos and piercing, plus sharing of personal items such as tooth brushes, razors and earrings can all lead to exposure to infected blood...

  • Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan. Umemura, Takeji; Tanaka, Eiji; Kiyosawa, Kendo; Kumada, Hiromitsu // Clinical Infectious Diseases;9/1/2008, Vol. 47 Issue 5, pe52 

    Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection was found in 23 (4%) of 552 newly hepatitis B surface antigen-positive patients in Japan. Because onefourth of cases develop into fulminant hepatic failure and mortality is 100%, management of HBV reactivation in...

  • The Prevention of Hepatitis B with Vaccine. Francis, Donald P.; Hadler, Stephen C.; Thompson, Sumner E.; Maynard, James E.; Ostrow, David G.; Altman, Norman; Braff, Erwin H.; O'Malley, Paul; Hawkins, Donald; Judson, Franklyn N.; Penley, Kent; Nylund, Thom; Christie, Graham; Meyers, Frank; Moore Jr., Joseph N.; Gardner, Ann; Doto, Irene I.; Miller, Joe H.; Reynolds, Gladys H. // Annals of Internal Medicine;Sep82, Vol. 97 Issue 3, p362 

    Presents information on a randomized placebo trial of the Merck hepatitis B virus (HBV) vaccine among homosexual men attending venereal disease clinics in the U.S. Details on HBV infections in humans; Materials and methods used in the study; Results.

  • Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Yeon, J. E.; Yoo, W.; Hong, S. P.; Chang, Y. J.; Yu, S. K.; Kim, J. H.; Seo, Y. S.; Chung, H. J.; Moon, M. S.; Kim, S.-O.; Byun, K. S.; Lee, C. H. // Gut;Oct2006, Vol. 55 Issue 10, p1488 

    Background: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naïve chronic hepatitis B patient (CHB) at weeks 48,...

  • Hepatitis B Virus Genotype and DNA Level in HCC.  // JNCI: Journal of the National Cancer Institute;2/16/2005, Vol. 97 Issue 4, p241 

    Reports on the findings that chronic hepatitis B virus (HBV) infection is a cause of hepatocellular carcinoma (HCC). Methods used to determine the role of HCC in HBV; Results that suggest measurements of HBV load and genotype may help to define which male HBV carriers are at high risk for HCC;...

  • The Prevalence of Hepatitis B Surface Antigen and Anti-Hepatitis B Core Antibody in Iran: A Population-Based Study. Merat, Shahin; Rezvan, Houri; Nouraie, Mehdi; Jamali, Arsia; Assari, Shervin; Aboighasemi, Hassan; Radmard, Amir-Reza; Zaer-Rezaii, Hanieh; Zeid-Abadi-Nejhad, Mahmood; Hosseini, Mohammad-Reza; Amini-Kafiabad, Sedigheh; Maghsudlu, Mahtab; Pourshams, Akram; Malekzadeh, Reza // Archives of Iranian Medicine (AIM);May2009, Vol. 12 Issue 3, p225 

    Background: Hepatitis B virus infection is a very common cause of chronic liver disease worldwide. It is estimated that 3% of Iranians are chronically infected with hepatitis B virus. Current population-based studies on both rural and urban prevalence of hepatitis B virus infection in Iran are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics